

University of Groningen

Means and methods for cloning nucleic acid sequences

Geertsma, Eric Robin ; Poolman, Berend

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2008

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Geertsma, E. R., & Poolman, B. (2008). Means and methods for cloning nucleic acid sequences. (Patent No. WO2008147193).

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 December 2008 (04.12.2008)

PCT

(10) International Publication Number
WO 2008/147193 A1

(51) International Patent Classification:
C12N 15/64 (2006.01) *C12N 15/74* (2006.01)

(21) International Application Number:
PCT/NL2008/050329

(22) International Filing Date: 30 May 2008 (30.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07109450.2 1 June 2007 (01.06.2007) EP
60/932,686 1 June 2007 (01.06.2007) US

(71) Applicant (for all designated States except US): **RIJK-SUNIVERSITEIT GRONINGEN** [NL/NL]; Broerstraat 5, NL-9712 CP Groningen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GEERTSMA, Eric Robin** [NL/NL]; Snelliusstraat 102, NL-9727 JR Groningen (NL). **POOLMAN, Berend** [NL/NL]; Botanicuslaan 8, NL-9751 AC Haren (NL).

(74) Agent: **HATZMANN, M.J.**; Vereenigde, Johan de Wittlaan 7, NL-2517 JR Den Haag (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with information concerning request for restoration of the right of priority in respect of one or more priority claims

(54) Title: MEANS AND METHODS FOR CLONING NUCLEIC ACID SEQUENCES

(57) Abstract: The invention provides means and methods for efficiently cloning nucleic acid sequences of interest in micro-organisms that are less amenable to conventional nucleic acid manipulations, as compared to, for instance, E.coli. The present invention enables high-throughput cloning (and, preferably, expressing) of a nucleic acid of interest in a first kind of micro-organism, while an initial (preferably high throughput) cloning of the nucleic acid of interest is done in a second kind of micro-organism.



WO 2008/147193 A1

Title: Means and methods for cloning nucleic acid sequences

5 The invention relates to the field of molecular biology.

Micro-organisms are an attractive host for amplifying and expressing nucleic acid.

Expression of nucleic acids which encode protein is a valuable tool for producing sufficient amounts of a protein of interest, such as for instance (therapeutic)

10 enzymes. Well-established expression hosts are *Escherichia coli* and yeast.

However, proteins produced this way do not always have the native conformation or they are not at all produced. For instance, proteins are not always folded correctly by the micro-organisms that produce them and may contain unwanted

15 post-translational modifications. Heterologous expression of large multidomain assemblies and membrane proteins in a functionally competent state is often problematic in the well-established expression hosts *E. coli* and yeast.

Alternative expression systems are thus urgently needed to overcome this major hurdle in structural genomics projects. Frequently, efficient DNA manipulations form a bottleneck for exploring the protein expression potential of novel hosts,

20 thereby preventing rapid and routine screening. Shuttle vectors that replicate both in *E. coli* and an alternative host offer a way out, but their use is complicated by the requirement for dual replication factors and multiple selection markers. This increases the plasmid size and often compromises stable

25 propagation. For instance, *Lactococcus lactis* is widely recognized as an attractive alternative to *E. coli* and yeast-based expression systems. However, the expression screening in *L. lactis* has been seriously hampered by the low efficiency of gene manipulations in the organism and the instability of *L. lactis* – *E. coli* shuttle vectors. Additionally, the lack of an efficient cloning procedure has restricted the preparation of large gene libraries for directed evolution studies in

30 *L. lactis*; similar limitations have prohibited the full exploitation of other micro-organisms as expression and screening hosts.

It is an object of the present invention to provide alternative means and methods for cloning a nucleic acid of interest in a micro-organism. Preferably,

35 means and methods are provided for cloning a nucleic acid of interest in a micro-

organism which is less amenable to conventional nucleic acid manipulations as compared to *E.coli*.

Accordingly, the present invention provides a method for cloning a nucleic acid sequence of interest in a first kind of micro-organism, the method comprising:

- inserting said nucleic acid of interest into a nucleic acid vehicle, which vehicle comprises an origin of replication of a second kind of micro-organism;
- cloning said vehicle in a culture of said second kind of micro-organism;
- isolating cloned vehicle comprising said nucleic acid sequence of interest;
- substituting the vehicle's origin of replication of a second kind of micro-organism by an origin of replication of said first kind of micro-organism; and
- cloning the resulting vehicle in a culture of said first kind of micro-organism.

Preferably, said first kind of organism is different from said second kind of organism, e.g. they might require distinct factors to stably propagate a cloning vehicle. Most preferably, said first kind of organism belongs to another species and or genus as compared to said second kind of microorganism. A preferred embodiment therefore provides a method according to the invention, wherein said first kind of organism and said second kind of organism are different from each other. They preferably belong to different species and/or genera. With a method of the invention it has become possible to efficiently clone nucleic acid sequences of interest in micro-organisms that are less amenable to conventional nucleic acid manipulations, as compared to *E.coli*. The present invention enables high-throughput cloning (and, preferably, expressing) of a nucleic acid of interest in a first kind of micro-organism, while an initial (preferably high-throughput) cloning of the nucleic acid of interest is done in a second kind of micro-organism. Preferably, a second kind of organism is used for which an origin of replication (ori) is available in the art, and/or for which a selection marker, such as for instance an antibioticum selection marker, is available. Said second kind of micro-organism is preferably *E.coli*. Said first kind of micro-organism is preferably any micro-organism other than *E.coli*. The need of shuttle vectors is circumvented. With a method of the invention it has become possible to take advantage of the cloning properties of both said first and said second kind of micro-organism. Said second micro-organism is preferably a kind of micro-organism with a high cloning efficiency, such as *E.coli*. Said first kind of micro-

organism preferably comprises an expression property of interest. Said first kind of micro-organism is for instance preferably capable of producing a protein of interest with a desired conformation.

5 In a first step of a method according to the invention a nucleic acid of interest is inserted into a nucleic acid vehicle, which vehicle comprises an origin of replication (ori) of a second kind of micro-organism. A nucleic acid vehicle is defined as a compound which comprises nucleic acid. Preferably, said nucleic acid vehicle consists of nucleic acid. The term "nucleic acid" encompasses sequences
10 comprising natural nucleotides (adenine, guanine, cytosine, thymine and/or uracil) and/or non-natural nucleotides (such as for instance inosine). Artificial nucleic acid analogues, such as for instance - but not limited to - peptide nucleic acid (PNA), are also encompassed by the term "nucleic acid".

 Said nucleic acid vehicle preferably comprises a plasmid or a vector. In
15 this first step, use is made of a nucleic acid vehicle which comprises an origin of replication of a second kind of micro-organism. Said origin of replication is a nucleic acid region which is necessary for initiation of replication of the nucleic acid vehicle. An origin of replication of a second kind of micro-organism is recognized by the nucleic acid replication machinery of said second kind of micro-
20 organism. Different micro-organisms require different kinds of replication origins; an origin-recognition protein of a micro-organism (e.g. DnaA in *E.coli*) is capable of binding to an origin of replication. Upon recognition, replication is started, which require additional proteins that can be specific for a given micro-organism. Hence, an origin of replication has to be chosen which is recognized by a micro-
25 organism of choice. If *E.coli* is chosen as a second kind of micro-organism, the *E.coli* origin of replication from pBR322, pSC101 or p15A is for instance used. If *B. subtilis* is chosen as a second kind of micro-organism, the *B. subtilis* origin of replication from pAM β 1 or pC194 is for instance used. However, any origin of replication of a micro-organism of choice is suitable.

30 A nucleic acid of interest is inserted into a nucleic acid vehicle using any cloning method available in the art. In a preferred embodiment, said nucleic acid of interest is inserted into said first vehicle and cloned in a culture of said second kind of micro-organism using a method selected from the group consisting of a Ligation Independent Cloning (LIC) procedure, Gateway, Univector Plasmid-
35 fusion System (UPS), and methods that are derived from LIC such as for instance

Enzyme-Free Cloning (EFC) or Sequence and Ligation Independent Cloning (SLIC). In one embodiment a ligation-independent cloning (LIC) procedure (Aslanidis and de Jong, 1990) is used. Contrary to methods that rely on recombination events (e.g., Gateway (Walhout et al, 2000) or the Univector Plasmid-fusion System (UPS) (Liu et al, 1998)), ligation-independent cloning is less restricted in the design of the sequences flanking the gene(s). Therefore, the cloning-related sequences attached to the recombinant protein(s) can be minimized. One embodiment of a LIC procedure is schematically outlined in Figure 1B. This embodiment of a LIC cloning procedure involves linearization of a vector by restriction at a unique *SwaI* site in the middle of the LIC cassette, followed by T4 DNA polymerase treatment to create long, defined single-stranded overhangs, complementary to those of a nucleic acid sequence (for instance a PCR product). The resulting vector and nucleic acid sequence are mixed and transformed to an expression host, for instance by chemical transformation using CaCl_2 . The LIC cassettes are preceded by promoter regions specific for the intended expression host. Ligation-independent cloning of nucleic acid products proved highly efficient for *E. coli* vectors, indicating that the length and composition of the complementary overhangs of vector and insert suffice for formation of stable heteroduplexes. In contrast, direct transformation of *L. lactis* with a stable heteroduplex of a LIC vector and a compatible insert yielded no or only very few positive clones. Therefore, a second micro-organism is preferably chosen which allows for efficient cloning, such as – but not limited to – *E.coli*.

In a second step of a method according to the invention, cloned vehicle comprising a nucleic acid of interest is isolated. This is done using any nucleic acid isolation method known in the art, such as for instance the method of Birnboim and Doly (1979).

Subsequently, the origin of replication of the cloned vehicle is substituted by an origin of replication of a first micro-organism. This is preferably done using a recombinase or, even more preferably, using a restriction enzyme. In that case the vehicle is designed such that a first recombinase site or restriction enzyme recognition sequence is present before the origin of replication of a second micro-organism. A second recombinase site or restriction enzyme recognition sequence is preferably present after said origin of replication. Upon incubation with a

recombinase or a restriction enzyme recognizing said sequences, the origin of replication is cut out of the vehicle. Subsequently, an origin of replication of a first micro-organism is inserted into the vehicle. The resulting vehicle is preferably essentially devoid of elements derived from said second kind of micro-organism in order to allow efficient cloning and maximal stability of the vehicle in said first kind of micro-organism. Hence, with a method according to the invention, the use of shuttle vectors is not necessary. This is advantageous because any additional sequence increases the size of the resulting vector. In order to be capable of efficient cloning, the size of the resulting vehicle is preferably as small as possible. Moreover, smaller vehicles are more stable. Hence, the presence of additional, foreign sequences unnecessarily enlarges the resulting vehicle, decreases the stability and decreases the maximum size that a nucleic acid sequence of interest is allowed to have. An embodiment of the present invention wherein the resulting vehicle is essentially devoid of elements derived from said second kind of micro-organism is therefore preferred. By essentially devoid is meant that the resulting vehicle comprises no more than 15, preferably no more than 10 nucleotides derived from said second kind of micro-organism. Moreover, the resulting vehicle preferably comprises no more than 100, more preferably no more than 50, most preferably no more than 30 "foreign" nucleotides originating from the recombinase recognition sites and/or restriction enzyme recognition sites of the original vehicle(s).

A non-limiting, preferred embodiment is schematically shown in figure 1A. According to this embodiment, a nucleic acid of interest is inserted into a first vehicle comprising an *E.coli* origin of replication. Said vehicle is amplified in *E.coli*. Subsequently, the vector is isolated and cut by the *Sfi*I restriction enzyme, preferably in the presence of another vector comprising an *L.lactis* origin of replication which is flanked by similar *Sfi*I sites. Upon treatment with T4 DNA ligase and ATP, the *E.coli* origin of replication of the first vehicle is subsequently replaced by the *L.lactis* origin of replication in a significant part of the vehicles. Of course, many alternative embodiments are within the scope of the present invention. Any way of exchanging any origins of replication is suitable.

In a subsequent step of a method according to the invention, resulting nucleic acid vehicles comprising a nucleic acid sequence of interest and an origin of replication of a first micro-organism are transformed in said first kind of

micro-organism. Said nucleic acid sequence of interest is preferably expressed in said first kind of micro-organism. This way, efficient cloning and expression of a nucleic acid of interest in any micro-organism for which plasmids are available has become feasible. Since a method of the invention allows the use of a second
5 kind of micro-organism more amenable to (high-throughput) cloning, the cloning efficiency limitations of many first kinds of micro-organisms are at least in part bypassed.

In a preferred embodiment at least two nucleic acid vehicles are used. One
10 vehicle comprises an origin of replication of a first kind of micro-organism and one vehicle comprises an origin of replication of a second kind of micro-organism. A nucleic acid sequence of interest is inserted into the vehicle comprising an origin of replication of a second kind of micro-organism and the resulting vehicle is transformed in said second kind of micro-organism. Subsequently, the origin of
15 replication of the vehicle containing the nucleic acid sequence of interest is replaced by the origin of replication of the other vehicle and the resulting vehicle is subsequently transformed in the first kind of micro-organism. A preferred embodiment thus provides a method according to the invention comprising:

- providing a first nucleic acid vehicle which comprises an origin of replication of
20 said second kind of micro-organism;
- introducing a nucleic acid sequence of interest into said first vehicle;
- providing a second nucleic acid vehicle which comprises an origin of replication of said first kind of micro-organism; and
- substituting a part of said first vehicle, which part comprises said origin of
25 replication of said second micro-organism but not said nucleic acid of interest, by a part of said second vehicle, said part comprising said origin of replication of said first microorganism.

Preferably said second vehicle comprises a complete origin of replication of said first kind of micro-organism. In one alternative embodiment said second
30 vehicle comprises a part of an origin of replication of said first kind of micro-organism. In this embodiment, said first vehicle preferably also comprises a part of said origin of replication of said first kind of micro-organism, which part is preferably not present in said second vehicle. After a nucleic acid of interest has been inserted into said first vehicle, a sequence of said second vehicle comprising
35 said part of an origin of replication of said first micro-organism is preferably


inserted into said first vehicle. In one embodiment a part of said origin of replication of said first micro-organism which is present in said first vehicle and a part of said origin of replication of said first micro-organism which is present in said second vehicle are functionally linked together, so that said parts are
5 capable of acting together. Said second vehicle preferably comprises a significant part, more preferably a functional part, of said origin of replication of said first kind of micro-organism.

The invention also provides means and methods for even further
10 optimizing nucleic acid manipulation efficiency. The present inventors have recognized that the use of restriction enzymes that produce different, non-palindromic overhangs that are not compatible with each other is preferred in order to enhance cloning efficiency. Non-limiting examples of such restriction enzymes are *SfiI*, *SapI*, *Ksp632I*, *AarI*, *BglI*, *PflMI* and *BstXI*. Said restriction
15 enzymes preferably recognize nucleic acid sequences that rarely occur in the genomes of prokaryotes and eukaryotes, so that unintentional cutting of nucleic acid inserts of interest is best avoided. In principle, the more specific base pairs a recognition site has, the smaller the chance is that it occurs in a given nucleic acid sequence. The recognition sites of *Ksp632I*, *BglI*, *PflMI* and *BstXI* have six
20 specific base pairs, the recognition sites of *SapI* and *AarI* have seven specific base pairs and the recognition site of *SfiI* has eight specific base pairs. Therefore, in order to even better avoid unintentional cutting of nucleic acid insert sequences of interest, a method according to the invention is preferably performed using *SapI*, *AarI* or *SfiI*. Most preferably, *SfiI* is used. The use of *SfiI* is particularly
25 preferred because for other restriction enzymes available in the art that produce different, non-palindromic overhangs that are not compatible with each other, the occurrence of recognized nucleic acid sequences in genomes is more frequent and/or the maximal combinations of protruding sequences is less than that of *SfiI*. Therefore, the application of *SfiI* is particularly efficient. Furthermore, a
30 restriction enzyme that is active in the same kind of buffer wherein T4 DNA ligase is active is preferred, so that in one embodiment cleavage reactions with at least one restriction enzyme and ligase reactions with T4 DNA ligase are carried out without need to change the reaction buffer, mere supplementation of the buffer with T4 ligase and ATP would suffice to start the ligation. *SfiI* is active in

the same kind of buffer wherein T4 DNA ligase is active. Therefore, *Sfi*I is also preferred because of this property.

By compatible is meant that two nucleic acid sequences are capable of binding each other because they comprise single stranded complementary sequences of a sufficient length. Hence, nucleic acid sequences that are not compatible with each other are not capable of annealing to each other because they do not comprise single stranded, complementary sequences of a sufficient length.

A particularly preferred restriction enzyme is *Sfi*I. *Sfi*I recognizes the sequence 5' GGCCNNNNNGGCC 3' (N being any nucleotide). The sequence is cut at:



As a result, an overhang of NNN is produced. Hence, as indicated in Figure 1C, nucleic acid cleavage by *Sfi*I generates a 3' overhang that can be composed of any combination of three nucleotides. In a preferred embodiment of a method of the present invention, a first nucleic acid vehicle is used which comprises preferably two different *Sfi*I sites, flanking an origin of replication of a second kind of micro-organism, which *Sfi*I sites, upon incubation with *Sfi*I, yield different, non-palindromic overhangs that are not compatible with each other. Incubation with *Sfi*I results in a cut vehicle which is devoid of the origin of replication of said second micro-organism. Two ends of this vehicle that has been cut by *Sfi*I do not anneal to each other. According to a further preferred embodiment, said two ends are capable of annealing to a second nucleic acid comprising a different origin of replication. This way, said second nucleic acid is very efficiently introduced into said vehicle.

Said second nucleic acid comprising a different origin of replication preferably originates from a second nucleic acid vehicle comprising said origin of replication, flanked by *Sfi*I sites. The *Sfi*I sites are chosen such that the resulting overhangs are compatible with the *Sfi*I overhangs of the above mentioned vehicle that has been cut by *Sfi*I. Upon incubation with *Sfi*I, the second vehicle is cut and a nucleic acid sequence is obtained which comprises an origin of replication of a

first micro-organism with *Sfi*I overhangs capable of annealing to said first vehicle which has been cut by *Sfi*I.

A preferred embodiment thus provides a method for cloning a nucleic acid
5 sequence of interest in a first kind of micro-organism, the method comprising:
- providing a first nucleic acid vehicle which comprises an origin of replication of
said second kind of micro-organism;
- introducing a nucleic acid sequence of interest into said first vehicle;
- providing a second nucleic acid vehicle which comprises an origin of replication
10 of said first kind of micro-organism; and
- substituting a part of said first vehicle, which part comprises said origin of
replication of said second micro-organism but not said nucleic acid of interest, by
a part of said second vehicle, said part comprising said origin of replication of
said first microorganism, wherein said part of said first vehicle has different,
15 non-palindromic overhangs that are not compatible with each other. Preferably,
said overhangs are compatible with the overhangs of said part of said second
vehicle.

Said parts are preferably obtained by cleavage of said vehicles by *Sfi*I.

An advantage of a method according to the invention is the fact that
20 manipulations of said first and second vehicle are carried out without the need
for purification of the vehicle fragments. Hence, methods according to the
invention allow for minimal sample handling and automation of the methods.

A method of the invention involves transformation of nucleic acid
25 sequences of interest to micro-organisms. In order to select micro-organisms that
comprise the nucleic acid sequences of interest, selection markers are preferably
used. Preferably, a nucleic acid sequence comprising an origin of replication of a
first kind of micro-organism together with a first selection marker is used.
Additionally, or alternatively, a nucleic acid sequence comprising an origin of
30 replication of a second kind of micro-organism together with a second selection
marker is preferably used. A non-limiting example of a suitable selection marker
is a gene which provides resistance against the action of an enzyme and/or
antibiotic, such as for instance a chloramphenicol resistance gene or a beta-
lactam antibiotic resistance gene. Alternatively, or additionally, a selection
35 marker is used that complements an auxotrophy (e.g. biosynthetic deficiency) in

the microorganism in which the nucleic acid sequences are preferably expressed, such as for instance the *alr* gene, encoding an alanine racemase (Bron et al, 2002), or allows selection based on alternative selection procedures, such as for instance the *shsp* gene, encoding a small heat shock protein (El Demerdash et al, 2003). If
5 a nucleic acid sequence is coupled to a selection marker, the presence of said nucleic acid sequence in a micro-organism is determined by determining whether the selection marker is present. For instance, an origin of replication of a second kind of micro-organism is coupled to a beta-lactamase resistance gene. After transformation, the resulting micro-organisms are propagated in the presence of
10 beta-lactamase. Micro-organisms that are propagated apparently carry the beta-lactamase resistance gene which indicates that they also carry the origin of replication of a second kind of micro-organism.

A non-limiting example of the use of selection markers is schematically depicted in Figure 1A. A vector comprising an *E.coli* origin of replication is
15 provided with a nucleic acid sequence of interest and transformed in *E.coli*. This vector has both a chloramphenicol resistance gene (*cat*) and a beta-lactamase resistance gene (*bla*). *E.coli* micro-organisms carrying this vector are resistant to beta-lactamase. Subsequently, the *E.coli* origin of replication is replaced by an *L.lactis* origin of replication. The resulting vector does no longer comprise the
20 beta-lactamase resistance gene, but does contain the *L.lactis* origin of replication. Hence, *L.lactis* clones that are resistant to chloramphenicol contain a nucleic acid vehicle containing both the chloramphenicol resistance gene and the *L.lactis* origin of replication which allows propagation of the nucleic acid in *L.lactis*. Of course, many other (combinations of) selection markers are suitable for selecting
25 micro-organisms of interest.

Further provided is therefore a method for cloning a nucleic acid sequence of interest in a first kind of micro-organism, the method comprising:

- providing a first nucleic acid vehicle which comprises an origin of replication of a second kind of micro-organism;
- 30 - introducing a nucleic acid sequence of interest into said first vehicle;
- providing a second nucleic acid vehicle which comprises an origin of replication of said first kind of micro-organism; and
- substituting a part of said first vehicle, which part comprises said origin of replication of said second micro-organism but not said nucleic acid of interest, by
35 a part of said second vehicle, said part comprising said origin of replication of

said first microorganism, wherein said part of the first vehicle comprising an origin of replication of said second micro-organism comprises a selection marker, such as for instance a resistance gene. In one embodiment said second vehicle comprising an origin of replication of said first micro-organism comprises a
5 different selection marker, such as for instance a different resistance gene.

A method according to the present invention is particularly suitable for improving the efficiency of cloning and expressing a nucleic acid sequence of interest in a micro-organism of interest. Preferably, a first cloning step is
10 performed wherein a nucleic acid of interest is efficiently inserted into a nucleic acid vehicle and cloned in another kind of micro-organism which has better cloning properties as compared to the micro-organism wherein the nucleic acid of interest is finally expressed. Preferably, a second kind of organism is used which is capable of more efficiently cloning a nucleic acid of interest as compared to said
15 first kind of micro-organism. For instance, a second kind of organism for which an origin of replication (ori) is available in the art, and/or for which a selection marker, such as for instance an antibioticum selection marker, is available in the art, is preferably used. One embodiment thus provides a method for cloning a nucleic acid sequence of interest in a first kind of micro-organism, the method
20 comprising:

- providing a first nucleic acid vehicle which comprises an origin of replication of a second kind of micro-organism;
- introducing a nucleic acid sequence of interest into said first vehicle;
- cloning said vehicle in a culture of said second kind of micro-organism;
- 25 - providing a second nucleic acid vehicle which comprises an origin of replication of said first kind of micro-organism;
- substituting a part of said first vehicle, which part comprises said origin of replication of said second micro-organism but not said nucleic acid of interest, by a part of said second vehicle, said part comprising said origin of replication of
30 said first microorganism; and
- cloning the resulting vehicle in a culture of said first kind of micro-organism;

wherein the process of inserting said nucleic acid of interest into said first vehicle and cloning it in a culture of said second kind of micro-organism is more efficient as compared to a process of inserting said nucleic acid of interest into
35 said second vehicle and cloning it in a culture of said first kind of micro-organism.

In one preferred embodiment said first and said second kind of micro-organisms are bacteria. Preferably, said second kind of micro-organism is *E.coli* and said first kind of micro-organism is a micro-organism different from *E.coli*.

A method according to the invention is particularly suitable for efficient
5 cloning of a nucleic acid of interest and expression of said nucleic acid of interest in a micro-organism for which efficient cloning methods are not available in the art. Such micro-organisms are called herein recalcitrant micro-organisms. Recalcitrant micro-organisms are defined herein as micro-organisms in which, with the technology currently available, it is difficult to clone a nucleic acid of
10 interest. As used herein, it is typically difficult to clone a nucleic acid of interest if less than 1000 colony forming units per μg nucleic acid are formed during the cloning procedure. With recalcitrant micro-organisms it is difficult to make gene constructs at a medium -to high- throughput rate, meaning that transformation of these organisms with ligation mixtures generally results in low transformation
15 efficiencies (generally less than 1000 colony forming units per μg DNA). As used herein, gene constructs encompass, but are not limited to, homologous genes and/or nucleic acid sequences to be inserted in a vehicle. In some embodiments, said gene constructs comprise nucleic acid sequences that have been mutated, for instance by error-prone PCR, and for which screening of large plasmid libraries is
20 desired.

Contrary to prior art methods such as the methods disclosed in WO 96/40724 and WO 00/29000, which exchange nucleic acid sequences between vectors where after the resulting vector of interest is cloned in the commonly
used *E.coli* bacteria, preferred methods according to the present invention
25 comprise efficient cloning of a nucleic acid of interest and expression of said nucleic acid of interest in a micro-organism other than *E.coli*, preferably in recalcitrant bacteria, for which efficient cloning methods are not available in the art. With a method according to the invention high throughput expression
procedures in recalcitrant micro-organisms have become possible.

30

In Table 3 a non-limiting list of well known recalcitrant micro-organisms available in the art is given. However, many more recalcitrant micro-organisms are known. Nucleic acid manipulation and/or nucleic acid cloning in recalcitrant micro-organisms is more difficult and/or less efficient as compared to *E.coli*. For
35 example, in a recent study the cloning of genes in *E. coli* and *L. lactis* were

compared, using existing technology (Surade et al, 2006). For *E. coli* the success rate was 216 out of 222, whereas for *L. lactis* the success rate was only 39 out of 71. Thus, even after numerous attempts the authors of Surade et al failed to clone 32 genes in *L.lactis*.

5 Contrary, much better results are obtained if a method according to the present invention is applied. For instance, as shown in the Examples, in embodiments of the invention wherein said first kind of micro-organism is *L.lactis* and wherein said second kind of micro-organism is *E.coli*, the initial cloning step has the same, high efficiency as standard *E. coli* vectors; for the
10 performed procedures according to the invention thus far not a single failure in the conversion process has been observed, with a current count of over 300 gene constructs.

 A preferred embodiment of the present invention therefore provides a method according to the invention wherein said first kind of micro-organism is a
15 recalcitrant micro-organism. In one embodiment said first kind of micro-organism is one of the well known micro-organisms listed in Table 3.

 In one embodiment said first micro-organism is for instance *Lactococcus lactis*, *Streptomyces* sp or *Sulfolobus solfataricus* but most microorganisms
20 known to date are relevant in this context. Micro-organisms other than *E.coli* are often preferred because various proteins are better expressed by these micro-organisms as compared to *E.coli*. For instance, various proteins obtain a better conformation and/or post-translational modification(s) as a result of the cellular environment of other micro-organisms, as compared to *E.coli*. Moreover,
25 additional parameters such as their codon usage, types and quantities of chaperones, resistance to expression of proteins which are toxic to *E. coli*, and lipid composition of the plasma membrane is often more favorable to protein expression in a functional state as compared to *E.coli*. Micro-organisms other than *E.coli* are also preferred for expressing proteins if the produced proteins are
30 more stable in their close to own cellular environment. Hence, even though a conventional cloning procedure such as a LIC procedure is much less efficient in for instance *L.Lactis*, *Streptomyces* sp or *S. solfataricus*, as compared to *E.coli*, it is often still preferable to clone and express a nucleic acid sequence in micro-organisms other than *E.coli*. With a method according to the invention, efficient

cloning and expression of nucleic acid sequences in recalcitrant micro-organisms has become possible.

A method according to the invention is preferably provided wherein said
5 second micro-organism is *Escherichia coli*, because this micro-organism is known to have high transformation efficiencies and various gene manipulation tools have been specifically developed and optimized for this organism. This is amongst other things due to the fact that suitable origins of replications and plasmid systems exist in the art. Insertion of nucleic acids of interest into such
10 plasmid systems and cloning of the resulting plasmids have proven to be very efficient in *E.coli*. This micro-organism is therefore very suitable for use in a first cloning step of a method according to the invention.

Hence, in a particularly preferred embodiment, second micro-organism is *Escherichia coli*. As demonstrated in the Examples, *E.coli* is very suitable for
15 efficient nucleic acid cloning during the first phase of a method according to the invention.

A method according to the invention is particularly suitable for efficient cloning and expressing a nucleic acid sequence of interest by a micro-organism of
20 choice, preferably by a recalcitrant micro-organism. A method according to the invention, further comprising allowing expression of said nucleic acid of interest by a culture of said first kind of micro-organism is therefore also herewith provided. Once a nucleic acid of interest is expressed in a micro-organism with a method according to the invention, such expression product is preferably
25 obtained for further use. For instance, a therapeutic protein is produced, isolated and used for the preparation of a medicament. Many methods for obtaining, isolating and/or purifying protein that has been produced by micro-organisms are known in the art. Non-limiting examples include the use of affinity tags such as oligo-His-tags in combination with metal-chelate affinity chromatography, MBP-
30 tags in combination with amylose-resin affinity chromatography and other generic chromatography methods to purify proteins. A method according to the invention, further comprising obtaining an expression product of said nucleic acid sequence of interest is therefore also herewith provided, as well as an expression product obtained by a method according to the invention.

In one embodiment said nucleic acid of interest encodes a multidomain protein and/or a membrane protein. Heterologous expression of such proteins in a functionally competent state is often problematic in the well-established expression hosts *E.coli* and yeast. With a method of the invention, however, efficient cloning and expression of nucleic acid sequences encoding such proteins in alternative expression hosts has become possible.

Now that it has become possible to efficiently clone and express nucleic acid sequences in a wide variety of micro-organisms, a method of the invention is performed for many applications. For instance, nucleic acid sequences are mutated (for instance using error-prone PCR) and the resulting nucleic acid sequences are cloned and expressed. High-throughput screening of mutated proteins in order to look for improved variants has become possible. Micro-organisms other than the well-established *E.coli* are now used for high-throughput expression. Mutant proteins that do not obtain a desired conformation or post-translational modification in *E.coli* are now efficiently expressed using other kinds of micro-organisms. A cloning assay wherein a nucleic acid of interest is cloned and expressed by a method according to the invention is therefore also provided. Said cloning assay is preferably a high-throughput cloning assay.

Further provided is a kit of parts comprising:

- a first nucleic acid vehicle which comprises an origin of replication of a second kind of micro-organism; and
- a second nucleic acid vehicle which comprises an origin of replication of a first kind of micro-organism;

wherein each vehicle comprises at least two recombinase sites and/or restriction enzyme cleavage sites wherein said recombinase sites and/or restriction enzyme cleavage sites are preferably not present within said origins of replication. This way, the origins of replication are cut out of the vector and exchanged by the other kind of origin of replication at will.

Preferably, each vehicle comprises at least two restriction enzyme cleavage sites which, upon cleaving, yield two different, non-palindromic overhangs that are not compatible with each other so that two ends of a vehicle that has been cut do not anneal to each other. This way, cloning efficiency is even

further enhanced. When non-complementary, non-palindromic overhangs are used, a nucleic acid sequence of interest is in principle only capable of being inserted into a nucleic acid vehicle in one direction. Non-complementary, non-palindromic overhangs are therefore preferred in order to obtain a nucleic acid vehicle with a nucleic acid sequence of interest in the right orientation. Preferably, said first kind of micro-organism is different from said second kind of micro-organism. More preferably, said first kind of micro-organism belongs to another species and or genus as compared to said second kind of micro-organism. Said first kind of micro-organism preferably comprises a micro-organism other than *E.coli*. In a particularly preferred embodiment said first kind of micro-organism is a recalcitrant micro-organism.

In one embodiment said first nucleic acid vehicle comprises a sequence encoding an affinity tag (such as for instance a His-tag) and/or another kind of fusion partner (such as for instance GFP), which affinity tag or fusion partner will become attached to the protein(s) encoded by the nucleic acid sequence of interest. Such affinity tag or fusion partner facilitates isolation, and/or detection, and/or purification of said protein(s).

Such kit of parts is particularly suitable for performing a method according to the invention, wherein a nucleic acid sequence of interest is introduced into said first vehicle, where after the resulting vehicle is cloned in a culture of said second kind of micro-organism, where after the cloned vehicle's origin of replication is replaced by the origin of replication of said second vehicle, where after the resulting vehicle is cloned in a culture of said first kind of micro-organism. Said origins of replications are preferably separated from the vehicles where they are originally present by the action of a recombinase or one or more restriction enzymes. Therefore, recombinase sites and/or restriction enzyme cleavage sites are preferably present in the flanking regions of said origins of replication.

A kit of parts according to the invention preferably comprises a first and a second vehicle, wherein each vehicle comprises the same kind of restriction enzyme cleavage sites which, upon cleaving, yield two different, non-palindromic overhangs that are not compatible with each other so that two ends of a vehicle

that has been cut do not anneal to each other. This way, cloning efficiency is even further enhanced. The restriction enzyme sites of the vehicles are preferably chosen such that, upon incubation with said restriction enzyme, the parts of the vehicles that are intended to be ligated to each other have complementary single stranded overhangs. Preferably, at least one vehicle of a kit of parts according to the invention has at least two *Sfi*I cleavage sites. Most preferably, all vehicles of a kit of parts according to the invention have at least two *Sfi*I cleavage sites.

One preferred embodiment provides a kit of parts according to the invention, wherein said first vehicle comprises an *Escherichia coli* origin of replication. As already outlined before, *E.coli* is particularly suitable for the first cloning step of a method according to the invention. In one embodiment said *Escherichia coli* origin of replication is derived from pBR322.

The second vehicle of a kit of parts according to the invention preferably comprises an origin of replication of a micro-organism other than *E.coli*, preferably an origin of replication of a recalcitrant micro-organism. These micro-organisms are preferred for the production of various kinds of (human) proteins, as discussed before. In one embodiment a *Lactococcus lactis* origin of replication is used which is derived from pSH71.

The first vehicle of a kit of parts according to the invention preferably comprises a selection marker, such as for instance an antibiotic resistance gene. Furthermore, the second vehicle of said kit of parts preferably comprises a selection marker, such as for instance an antibiotic resistance gene. Selection markers are used for selection of micro-organisms which carry the nucleic acid vehicle, as explained herein before.

With a method according to the invention it has become possible to efficiently clone a nucleic acid of interest using a kind of micro-organism which is less amenable to conventional nucleic acid manipulations. For instance, a *Lactococcus lactis* culture has been obtained wherein the amount of colony forming units per microgram nucleic acid which was used in said method is at least 10^5 CFU/ μ g DNA.

Further provided is therefore a *Lactococcus lactis* culture obtainable by a method according to the invention, wherein the amount of colony forming units

per microgram nucleic acid of interest which was used in said method is at least 10^5 CFU/ μ g DNA.

The invention also provides a recombinant micro-organism comprising a
5 nucleic acid vehicle, which vehicle comprises:
- an origin of replication of said kind of micro-organism;
- a nucleic acid sequence of interest; and
- at least two restriction enzyme cleavage sites which, upon cleaving, yield two
different, non-palindromic overhangs that are not compatible with each other and
10 wherein said restriction enzyme cleavage sites are not present within said origins
of replication. Said micro-organism is preferably a micro-organism other than
E.coli. In one preferred embodiment said micro-organism is a recalcitrant micro-
organism. In one embodiment said micro-organism is *Lactococcus lactis*.

Moreover, said restriction enzyme cleavage sites are preferably *SfiI*, *SapI*,
15 *Ksp632I*, *AarI*, *BglI*, *PflMI* and/or *BstXI* cleavage sites, more preferably *SapI*,
AarI or *SfiI* cleavage sites. Most preferably, said restriction enzyme cleavage
sites are *SfiI* cleavage sites. As described herein before, the use of *SfiI*, *SapI*,
Ksp632I, *AarI*, *BglI*, *PflMI* and/or *BstXI* allows cleavage of a nucleic acid vehicle,
whereby two ends of a vehicle that has been cut do not anneal to each other. *SfiI*,
20 *SapI*, *Ksp632I*, *AarI*, *BglI*, *PflMI* and/or *BstXI* cleavage sites are designed such
that the parts of two different vehicles that are intended to be ligated to each
other have complementary single stranded overhangs. The use of *SfiI* further
provides the additional advantage that it is active in the same kind of buffer
wherein T4 DNA ligase is active. Hence, in a preferred embodiment wherein T4
25 DNA ligase and *SfiI* are used, the cleavage reactions and ligase reactions are
carried out without need to change the reaction buffer (meaning that actions
other than the administration of *SfiI*, T4 DNA ligase and ATP are not necessary).

The invention is further explained in the following examples. These
30 examples do not limit the scope of the invention, but merely serve to clarify the
invention.

Examples

We now present a generic cloning strategy, compatible with high-throughput manipulations, that generates a native plasmid vector optimal for the expression host and devoid of alien (e.g., *E. coli*-derived) elements. The Vector Backbone Exchange (VBEx) procedure presented here is specific for cloning in *L. lactis* but readily adaptable for all organisms for which a plasmid, selection marker and transformation method are available. VBEx has been used to generate over 300 gene constructs, and gene cloning up to expression screening in *L. lactis* has been carried out at a rate of 48 per week.

To facilitate the initial steps in the cloning of large numbers of open reading frames, we employed a ligation-independent cloning (LIC) procedure (Aslanidis and de Jong, 1990). Contrary to methods that rely on recombination events (e.g., Gateway (Walhout et al, 2000) or the Univector Plasmid-fusion System (UPS) (Liu et al, 1998)), ligation-independent cloning is less restricted in the design of the sequences flanking the gene(s). Therefore, the cloning-related sequences attached to the recombinant protein(s) can be minimized. The cloning procedure involves linearization of the vector by restriction at a unique *SwaI* site in the middle of the LIC cassette, followed by T4 DNA polymerase treatment to create long, defined single-stranded overhangs, complementary to those of the PCR product (Fig. 1B). The LIC cassettes are preceded by promoter regions specific for the intended expression host. Here, we used the P_{BAD} and P_{NIS} promoters of the *E. coli* and *L. lactis* expression plasmids pBAD24 (Guzman et al, 1995) and pNZ8048 (de Ruyter et al, 1996), respectively. Ligation-independent cloning of PCR products proved highly efficient for the *E. coli* vectors, indicating that the length and composition of the complementary overhangs of vector and insert suffice for formation of stable heteroduplexes. In contrast, direct transformation of *L. lactis* with the stable heteroduplex of the pNZ8048-derived LIC vector and a compatible insert yielded no or only very few positive clones (data not shown).

To overcome the poor cloning efficiencies in *L. lactis*, a new strategy (VBEx) was devised that allowed the initial (high-throughput) cloning to be done in *E. coli*, but avoided the use of shuttle vectors. Although we have used VBEx in combination with LIC, the strategy is fully compatible with Gateway, UPS and

variations on LIC (e.g, Enzyme Free Cloning (de Jong et al, 2007) and SLIC (Li and Elledge, 2007)). The method relies on the bisection of a *bona fide* plasmid vector of the expression host into two parts, thereby separating the selection marker and the origin of replication. For *L. lactis*, the origin of replication of the pNZ8048 plasmid (pSH71 replicon) was separated from the chloramphenicol resistance gene (*cat*) (Fig. 1a). The segment containing the *cat* and LIC sequence was fused to the backbone of a vector containing an *E. coli* origin of replication and the β -lactamase resistance gene (*bla*). The resulting plasmid, pRExLIC, allows the LIC manipulation to take place in *E. coli*. The segment containing the *L. lactis* origin of replication was fused to an erythromycin selection marker (yielding plasmid pERL), which enables replication and selection in the expression host.

Rapid and high-throughput compatible reconstruction of the original *L.lactis* expression plasmid from the relevant segments of pRExLIC and pERL is assured by flanking the ends of each half with distinct *Sfi*I restriction sites (*Sfi*I_x and *Sfi*I_y in Fig. 1a). DNA cleavage by *Sfi*I generates a 3' overhang that can be composed of any combination of three nucleotides. The two *Sfi*I sites used, yield different, non-palindromic overhangs that are not compatible with each other (Fig. 1c). The combination of i) both halves of the original expression vector having properties that can be selected for, and ii) different 3' overhangs after *Sfi*I digestion at either side of each plasmid segment, ensures minimal sample handling and allows automation of the method. As each half of the expression vector has unique selectable properties, no gel electrophoresis and purification of the *Sfi*I-fragments is required. Selection for the ability of the plasmid to replicate in *L. lactis* in the presence of chloramphenicol permits unique recovery of only the original expression vector from a complex mixture of *Sfi*I-digested pRExLIC and pERL plasmids. Furthermore, no change of buffers between the digestion and ligation reaction is needed. Mere supplementation of the *Sfi*I-buffer with ATP suffices for the T4 DNA ligase to be fully active.

In practice, the whole procedure can take place in a single tube in 3 hours. After joined *Sfi*I digestion of pRExLIC and pERL (80 min at 50°C), and subsequent heat inactivation of the restriction enzyme (20 min at 80°C), ligation (60 min at 20°C) of the fragments is started by the addition of ATP and T4 DNA ligase. Upon thermal inactivation of the T4 DNA ligase (20 min at 65°C), aliquots of the mixture can be used for (electro-)transformation without further

purification (Fig. 1). For *L. lactis*, we routinely observe high, reproducible transformation efficiencies ($\sim 10^6$ CFU/ μ g DNA), in comparison to the low, variable efficiencies of traditional restriction-ligation cloning ($\sim 10^2$ CFU/ μ g DNA; e.g. see Surade et al, 2006)). Notably, with the VBEx procedure, all *L. lactis* transformants obtained carry the gene of interest inserted in pNZxLIC. Using this system, we generated over 300 expression constructs and assessed protein levels at a rate of 48 constructs per week without robotics. The overexpression of a small subset of membrane proteins in *L. lactis* is presented in Fig. 1d.

Importantly, DNA sequences from virtually all sequenced genomes are compatible with the cloning strategy, because *Sfi*I sites (5' GGCCNNNN[^]NGGCC 3') are rare (Fig 2a). Analysis of all predicted gene transcripts of 492 archaeal and bacterial chromosomes and 30 eukaryotic genomes, present in the NCBI databank (February 2007) and Ensembl (release 43), respectively, indicated that well over 92% of these transcripts do not contain any *Sfi*I site (Table 1). Moreover, use of the method is not limited to transcripts free of *Sfi*I sites. As 64 different 3' overhangs may be generated after *Sfi*I digestion, internal *Sfi*I sites with 3' overhangs not matching those of the vector will result in a three or more-way ligation, but not form a bottleneck for the procedure. If needed, the vector can be readily adapted to use non-occurring or extremely rare overhangs. In 89% of the genomes analyzed at least two types of *Sfi*I overhangs do not occur (Fig 2b). The remaining 11% of the genomes contain several types of low occurrence *Sfi*I overhangs.

To ensure the generality of the presented strategy towards inserts of different size, we compared *Sfi*I digestion rates of pRExLIC derivatives holding inserts up to 3.7 kb (data not shown) and observed complete digestion after 80 min incubation. Furthermore, we demonstrated the absence of expression from the *P_{NIS}* promoter in the cloning host *E. coli*, using a sensitive activity based assay (data not shown). The success of assembly and stability in the pRExLIC and pNZxLIC vectors of recombinant DNA from bacterial, plant and mammalian origin proved very high and gene rearrangements have so far not been observed (n >300).

In summary, we have developed LIC-VBEx, a high-throughput compatible cloning system for *L. lactis* with unprecedented high efficiency, which can be readily adapted for any other expression host. Problems arising from shuttle vectors are avoided by using genuine expression plasmids. The LIC cassettes

developed allow the tagging of the protein of interest with a cleavable decaHis-tag at either the N- or C-terminus (vectors holding these cassettes and derivatives with alternative tags or fusion-partners are shown in Materials and Methods section). The procedure described has thus far been used in our lab to
5 prepare over 300 gene constructs with high efficiencies (~90% for LIC; 100% for VBEx (data not shown)). In a non-automated setting, the full procedure from cloning to expression screening in *E. coli* and *L. lactis*, took place at a rate of approximately 48 constructs per week.

Materials and methods

Ligation-Independent Cloning (LIC). Inserts were amplified using Phusion DNA polymerase (Finnzymes) and gene specific primers extended at the 5' side with LIC specific tails (Table A). Vectors containing a LIC cassette were purified using a plasmid isolation kit (Wizard® Plus, Promega). DNA was additionally purified by extraction with phenol:chloroform and chloroform to remove tracer amounts of proteins. Vectors (~5 µg of DNA) were digested overnight with 25 units of *SwaI* (Roche) at 25°C. PCR products and digested vectors were subsequently gel purified (GFX PCR DNA & Gel Band Purification Kit, GE), eluted in 10 mM Tris-HCl, pH 7.5, 0.2 mM Na-EDTA, and stored at 4°C.

200 ng of *SwaI*-digested vector and equimolar quantities of inserts were treated separately with 0.5 U T4 DNA polymerase (Roche) at 20°C for 30 min in the presence of 2.5 mM dCTP and 2.5 mM dGTP, respectively, followed by heat inactivation of the T4 DNA polymerase (20 min at 75°C). The material, now in a "LIC-ready" state, can be stored at 4°C for prolonged periods (over 6 months). LIC-ready vector (1 µl) and insert (3 µl) were mixed and after a 5 min incubation at RT transformed to 75 µl chemically-competent *E. coli* MC1061. Cells were plated on Luria Broth supplemented with ampicillin (100 µg / ml).

Table A. Primer extensions required for Ligation Independent Cloning.

Type of primer	Sequence (5'→3')
nLIC forward	AT GGT GAG AAT TTA TAT TTT CAA GGT + gene specific
nLIC reverse	T GGG AGG GTG GGA TTT TCA TTA + gene specific
cLIC forward	ATG GGT GGT GGA TTT GCT + gene specific
cLIC reverse	TTG GAA GTA TAA ATT TTC + gene specific

Vector Backbone Exchange. Exchange of the vector backbone of pRExLIC-derived vectors was done in a small volume (10 µl) in a PCR machine with heated lid to avoid condensation. The pERL vector (containing the *L. lactis* origin of replication) and a pRExLIC-derived vector (containing the *L. lactis cat* gene) were mixed (~125 ng each) and the volume was adjusted to 10 µl by adding 1 µl 10 X buffer (100 mM Tris-HCl, pH 7.5, 100 mM MgCl₂, 500 mM NaCl, 1 mg/ml BSA), 5 U *SfiI* (Fermentas) and sufficient milliQ. The sample was incubated for

- 80 min at 50°C, and 20 min at 80°C to inactivate *Sfi*I. After cooling to RT, ligation was started by the addition of 1.5 µl 8 mM Na₂-ATP, pH 7, and 0.5 U T4 DNA ligase (Roche). The sample was incubated for 1 hr at 20°C and 20 min at 65°C to heat inactivate the T4 DNA ligase. Subsequently, 2 µl of the sample was transformed to 30 µl electrocompetent *L. lactis* NZ9000 (see below) and aliquots were plated on M17 plates (Terzaghi and Sandine, 1975) (Difco) supplemented with 0.5% glucose, 0.5 M sucrose, 5 µg/ml chloramphenicol. Parafilm-sealed plates were incubated at 30°C until colonies appeared (~18 hrs).
- 10 **Electrotransformation of *L.lactis*.** Preparation of electrocompetent *L. lactis* NZ9000 was essentially done as described (Holo and Nes, 1989; Wells et al, 1993), but with some critical modifications. Briefly, cells were grown in M17 supplemented with 0.5% glucose, 0.5 M sucrose and 2% glycine at 30°C to OD₆₀₀ = ~0.5. Cells were harvested by centrifugation at 5000 x *g* for 15 min at 4°C.
- 15 Following washes with 1 volume ice-cold solution A (0.5 M sucrose and 10% glycerol, prepared in milliQ), 0.5 volume solution A supplemented with 50 mM Na-EDTA, pH 7.5, and 0.25 volume solution A, cells were resuspended in 0.01 volume solution A. Aliquots of 40 µl were flash-frozen in liquid nitrogen and stored at -80°C until use. For electroporation, cells were thawed on ice, combined
- 20 with plasmid DNA, and transferred to an ice-cooled electroporation cuvet (2 mm gap). Cells were exposed to a single electrical pulse with a field strength of 2 kV, 25 µF capacitance and 200Ω resistance. Immediately following discharge, cells were mixed with 1 ml ice-cold M17 supplemented with 0.5% glucose, 0.5 M sucrose, 20 mM MgCl₂ and 2 mM CaCl₂, and left on ice for 10 min. Subsequently,
- 25 cells were incubated at 30°C for 2 hrs and aliquots were plated on M17 agar supplemented with 0.5% glucose, 0.5 M sucrose and 5 µg / ml chloramphenicol. was added. Plates were sealed and incubated overnight at 30°C.

Table 1 . Analysis of the distribution of *Sfi*I sites over pro- and eukaryotic gene transcripts. For the pro- and eukaryotic datapoints, 1.484.533 and 745.558 gene transcripts were analyzed, respectively.

<i>Sfi</i>I sites in transcript	Percentage of transcripts	
	prokaryotes	eukaryotes
0	92.18	92.06
1	6.42	6.49
2	1.09	1.04
3	0.22	0.23
4	0.06	0.08
5	0.02	0.03
6	0.01	0.02
7	0.00	0.01
8	0.00	0.01
9	0.00	0.01
>9	0.00	0.02

Detailed overview of the LIC process.

nLIC cassette: A construct is made that contains an N-terminal 10 His-tag, followed by a TEV protease cleavage site and Your Favorite Protein (YFP). Using the 3'→5' exonuclease activity of T4 DNA polymerase and dedicated tail-sequences, long defined overhangs are generated. These overhangs have a sufficiently high annealing temperature that mere mixing of complementary overhangs suffices in generating stable DNA sequences, ready for cell transformation.

- 10 The vector holds the nLIC cassette which contains a *SwaI* site. After *SwaI* digestion, the vector is treated with T4 DNA polymerase in the presence of **dCTP**, in order to generate the *nLIC-ready* overhangs (illustrated below).

15 **1. nLIC cassette**
 N Met His His His His His His His His His His Gly Glu Asn Leu Tyr
 5' ATG CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT GGT GAG AAT TTA TAT TTAATCCCACCCTCCCAG
 3' TAC GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA CCA CTC TTA AAT ATA AATTTAGGGTGGGAGGGTC

20 **2. After digestion with *SwaI***
 N Met His His His His His His His His His His Gly Glu Asn Leu Tyr
 5' ATG CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT GGT GAG AAT TTA TAT TT AAATCCCACCCTCCCAG
 3' TAC GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA CCA CTC TTA AAT ATA AA TTAGGGTGGGAGGGTC

25 **3. After treatment with T4 DNA polymerase + dCTP**
 N Met His His His His His His His His His His Gly Glu Asn Leu Tyr
 5' ATG CAT CAT CAC CAT CAT CAC CAT CAC CAT C AAATCCCACCCTCCCAG
 3' TAC GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA CCA CTC TTA AAT ATA AA C

- 30 The insert is PCR'd using primers with dedicated nLIC tails. After removal of primers and nucleotides, the insert is treated with T4 DNA polymerase in the presence of **dGTP**, in order to generate the nLIC-ready overhangs (illustrated below).

35 **1. PCR**
 N is Gly Glu Asn Leu Tyr Phe Gln Gly Met X X
 5' AT GGT GAG AAT TTA TAT TTT CAA GGT ATG YFP TAA TGA AAA TCC CAC CCT CCC A
 3' TA CCA CTC TTA AAT ATA AAA GTT CCA TAC YFP ATT ACT TTT AGG GTG GGA GGG T

40 **2. After treatment with T4 DNA polymerase + dGTP**
 N is Gly Glu Asn Leu Tyr Phe Gln Gly X X
 5' AT GGT GAG AAT TTA TAT TTT CAA GGT YFP TAA TG
 3' GTT CCA YFP ATT ACT TTT AGG GTG GGA GGG T

45

Subsequently, the nLIC-ready vector and insert are mixed. The defined overhangs anneal to stable structures with a T_m of approximately 44°C and 58°C for the 5' and 3' end of the gene, respectively. Small, 1 basepair gaps remain, which will be filled *in vivo*.

5 a. 5' end, before annealing

```

N Met His His His His His His His His His H is Gly Glu Asn Leu Tyr Phe Gln Gly
5' ATG CAT CAT CAC CAT CAT CAC CAT CAC CAT C AT GGT GAG AAT TTA TAT TTT CAA GGT YFP
3' TAC GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA CCA CTC TTA AAT ATA AA. GTT CCA YFP

```

10

b. 5' end, after annealing

```

N Met His His His His His His His His His His His Gly Glu Asn Leu Tyr Phe Gln Gly
5' ATG CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT GGT GAG AAT TTA TAT TTT CAA GGT YFP
3' TAC GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA CCA CTC TTA AAT ATA AA. GTT CCA YFP

```

15

20 1. 3' end, before annealing

```

N Met X X
5' ATG YFP TAA TG AAA TCC CAC CCT CCC AG
3' TAC YFP ATT ACT TTT AGG GTG GGA GGG T C

```

25

2. 3' end, after annealing

```

N Met X X
5' ATG YFP TAA TG. AAA TCC CAC CCT CCC AG
3' TAC YFP ATT ACT TTT AGG GTG GGA GGG TC

```

cLIC cassette: A construct is made that contains a relatively small N-terminal modification (MGGGFA), Your Favorite Protein (YFP), and a C-terminal TEV protease cleavage site followed by a 10 His-tag. Using the 3'→5' exonuclease

- 5 overhangs are generated. These overhangs have a sufficiently high annealing temperature that mere mixing of complementary overhangs suffices in generating stable DNA sequences, ready for cell transformation.

The vector holds the cLIC cassette which contains a *SwaI* site. After *SwaI* digestion, the vector is treated with T4 DNA polymerase in the presence of dCTP, in order to generate the *nLIC-ready* overhangs (illustrated below).

1. cLIC cassette

15
 5' C ATG GGT GGT GGA TTT A AAT TTA TAC TTC CAA GGT CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT TAA
 3' G TAC CCA CCA CCT AAA T TTA AAT ATG AAG GTT CCA GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA ATT

2. After digestion with *SwaI*

20
 5' C ATG GGT GGT GGA TTT A AAT TTA TAC TTC CAA GGT CAT CAT CAC CAT CAT CAC CAT CAC CAT CAC CAT TAA
 3' G TAC CCA CCA CCT AAA T TTA AAT ATG AAG GTT CCA GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA ATT

3. After treatment with T4 DNA polymerase + dCTP

25
 5' C M G G G F N L Y F Q G H H H H H H H H H H X
 3' G TAC CCA CCA CCT AAA A AAT TTA TAC TTC CAA GGT CAT CAT CAC CAT CAT CAC CAT CAC CAT CAC CAT TAA
 CCA GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA ATT

- 30 The insert is PCRred using primers with dedicated cLIC tails. After removal of primers and nucleotides, the insert is treated with T4 DNA polymerase in the presence of dGTP, in order to generate the cLIC-ready overhangs (illustrated below).

1. PCR

35
 5' ATG GGT GGT GGA TTT GCT YFP GAA AAT TTA TAC TTC CAA
 3' TAC CCA CCA CCT AAA CGA YFP CTT TTA AAT ATG AAG GTT

2. After treatment with T4 DNA polymerase + dGTP

40
 45
 5' ATG GGT GGT GGA TTT GCT YFP G
 3' GA YFP CTT TTA AAT ATG AAG GTT

Subsequently, the cLIC-ready vector and insert are mixed. The defined overhangs anneal to stable structures with a T_m of approximately 41°C and 31°C for the 5' and 3' end of the gene, respectively. Small, 1 basepair gaps remain, which will be filled *in vivo*.

5

a. 5' end, before annealing

M G G G F A

5' C ATG GGT GGT GGA TTT GCT YFP

3' G TAC CCA CCA CCT AAA GA YFP

10

b. 5' end, after annealing

M G G G F A

5' C ATG GGT GGT GGA TTT GCT YFP

3' G TAC CCA CCA CCT AAA .GA YFP

15

20

1. 3' end, before annealing

E N L Y F Q

5' YFP G A AAT TTA TAC TTC CAA GGT CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT TAA

3' YFP CTT TTA AAT ATG AAG GTT CCA GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA ATT

25

2. 3' end, after annealing

E N L Y F Q G H H H H H H H H H X

5' YFP G.A AAT TTA TAC TTC CAA GGT CAT CAT CAC CAT CAT CAC CAT CAC CAT CAT TAA

3' YFP CTT TTA AAT ATG AAG GTT CCA GTA GTA GTG GTA GTA GTG GTA GTG GTA GTA ATT

30

Brief description of the drawings

Figure 1. Outline of the LIC-VBEx strategy. (a) A scheme illustrating the bisection of the *L. lactis* expression vector pNZxLIC. The segment containing the *cat* and LIC sequence is placed on an *E. coli* backbone, yielding pRExLIC. This vector can subsequently be used for the LIC procedure (depicted in b). Derivatives of pRExLIC containing inserts are converted to pNZxLIC derivatives by the VBEx procedure. (c) The *Sfi*I sites flanking both segments of the plasmid vectors yield different overhangs. (d) Overexpression of membrane proteins in *L. lactis*. Left panels represent Coomassie stained protein gels, right panels immunoblots decorated with anti-His antibody. Minus and plus signs indicate samples uninduced and induced with nisin A. Filled and open arrows indicate His-tagged and non-tagged subunits/proteins, respectively. Marker bands are 170, 130, 100, 70, 55, 40, 35, 25, and 15 kDa. Shown are, from left to right: an ABC transporter and secondary riboflavin transporter from *L. lactis*, ABC transporters from *Staphylococcus aureus* and *Streptococcus pneumoniae*, and the integral membrane component of a TRAP transporter from *Haemophilus influenzae*; accession numbers are indicated below the panels.

20

Figure 2. Analysis of *Sfi*I characteristics. (a) The occurrence of *Sfi*I sites in 492 prokaryotic genomes and the concatenated gene transcripts of 30 eukaryotes as a function of the GC-content of the DNA. As 64 different overhangs can be generated after *Sfi*I digestion, the frequency of complementary *Sfi*I sites is even lower (Fig. 3). (b) The number of *Sfi*I overhangs not present in a genome or combined gene transcript as a function of the GC-content of the DNA (maximal 64). In rare cases where inserts would contain a *Sfi*I site interfering with the VBEx procedure, non-occurring overhangs could be used to flank both segments of the vector.

30

Figure 3. Analysis of the occurrence of *Sfi*I sites yielding identical overhangs in genomes and combined transcripts as a function of the GC-content of the DNA. For each DNA, the datapoint of the most occurring *Sfi*I site of this type is shown.

References

- Aslanidis, C and P. J. de Jong, *Nucleic Acids Res* **18** (20), 6069 (1990).
- 5 Birnboim and Doly, *Nucleic Acids Res.* 1979 Nov 24;7(6):1513-1523
- Bron PA, Benchimol MG, Lambert J, Palumbo E, Deghorain M, Delcour J, De Vos WM, Kleerebezem M, Hols P. Use of the *alr* gene as a food-grade selection marker in lactic acid bacteria. *Appl Environ Microbiol.* 2002 Nov;68(11):5663-70
- 10 de Jong, R. N. and M. A. Daniels, R. Kaptein et al., *J Struct Funct Genomics* (2007).
- de Ruyter, P. G. and O. P. Kuipers, and W. M. de Vos, *Appl Environ Microbiol* **62**
- 15 (10), 3662 (1996).
- El Demerdash HA, Heller KJ, Geis A. Application of the *shsp* gene, encoding a small heat shock protein, as a food-grade selection marker for lactic acid bacteria. *Appl Environ Microbiol.* 2003 Aug;69(8):4408-12.
- 20 Guzman, L. M. and D. Belin, M. J. Carson et al., *J Bacteriol* **177** (14), 4121 (1995).
- Holo, H and I. F. Nes, *Appl Environ Microbiol* **55** (12), 3119 (1989).
- 25 Li, M. Z. and S. J. Elledge, *Nat Methods* **4** (3), 251 (2007).
- Liu, Q and M. Z. Li, and D. Leibham et al., *Curr Biol* **8** (24), 1300 (1998).
- Surade, S. and M. Klein, P. C. Stolt-Bergner et al., *Protein Sci* **15** (9), 2178 (2006)
- 30 Terzaghi, B. E. and W. E. Sandine, *Appl Microbiol* **29** (6), 807 (1975).
- Walhout, A. J. and G. F. Temple and M. A. Brasch et al., *Methods Enzymol* **328**, 575 (2000).
- 35 Wells, J. M. and P. W. Wilson and R. W. Le Page, *J Appl Bacteriol* **74** (6), 629 (1993).

Table 2
Available LIC vectors.

WO 2008/147193

Vector name	Protein sequence	Protein sequence after TEV protease cleavage	Expression host
pREnLIC	M-His ₁₀ -G-TEV site-protein	G-protein	<i>L. lactis</i> NZ9000
pREcLIC	MGGGFA-protein-TEV site-His ₁₀	MGGGFA-protein-ENLYFQ	<i>L. lactis</i> NZ9000
pREcLIC-GFP	MGGGFA-protein-TEV site-GFP-His ₁₀	MGGGFA-protein-ENLYFQ	<i>L. lactis</i> NZ9000
pRE-USP45-nLIC	M-ssUSP45 ¹⁾ -His ₁₀ -G-TEV site-protein	G-protein	<i>L. lactis</i> NZ9000
pBADnLIC	M-His ₁₀ -G-TEV site-protein	G-protein	<i>E. coli</i>
pBADcLIC	MGGGFA-protein-TEV site-His ₁₀	MGGGFA-protein-ENLYFQ	<i>E. coli</i>
pBADcLIC-GFP	MGGGFA-protein-TEV site-GFP-His ₁₀	MGGGFA-protein-ENLYFQ	<i>E. coli</i>
pBAD-OmpA-nLIC	M-ssOmpA ²⁾ -His ₁₀ -G-TEV site-protein	G-protein	<i>E. coli</i>

¹⁾ ssUSP45 indicates the signal sequence of the *L. lactis* USP45 protein. The pRE-USP45-nLIC vector is used if the N-terminus of the membrane protein of interest is predicted to be on the outside of the cytoplasmic membrane, or to replace the signal sequence of the protein of interest with the ssUSP45.

²⁾ ssOmpA indicates the signal sequence of the *E. coli* OmpA protein. The pBAD-OmpA-nLIC vector is used if the N-terminus of the membrane protein of interest is predicted to be on the outside of the cytoplasmic membrane, or to replace the signal sequence of the protein of interest with the ssOmpA.

Table 3

Recalcitrant micro-organisms in terms of gene cloning (e.g. construction of gene libraries)
<i>Lactococcus lactis</i>
<i>Lactobacillus sp. (e.g. bulgaricus, helveticus, plantarum)</i>
<i>Sulfolobus solfataricus</i>
Archaea in general (incl. haloarchaea and others)
<i>Streptococcus sp. (e.g. thermophilus, pyogenes, mutans)</i>
<i>Leuconostoc sp.</i>
<i>Bacillus thermophilus, Bacillus caldotenax</i>

Claims

1. A method for cloning a nucleic acid sequence of interest in a first kind of micro-organism, the method comprising:
 - 5 - inserting said nucleic acid of interest into a nucleic acid vehicle, which vehicle comprises an origin of replication of a second kind of micro-organism;
 - cloning said vehicle in a culture of said second kind of micro-organism;
 - isolating cloned vehicle comprising said nucleic acid sequence of interest;
 - substituting the vehicle's origin of replication of a second kind of micro-
10 organism by an origin of replication of said first kind of micro-organism; and
 - cloning the resulting vehicle in a culture of said first kind of micro-organism.
2. A method according to claim 1, wherein said resulting vehicle is essentially devoid of elements derived from said second kind of micro-organism.
3. A method according to claim 1 or 2, comprising:
 - 15 - providing a first nucleic acid vehicle which comprises an origin of replication of said second kind of micro-organism;
 - introducing a nucleic acid sequence of interest into said first vehicle;
 - providing a second nucleic acid vehicle which comprises an origin of replication of said first kind of micro-organism; and
 - 20 - substituting a part of said first vehicle, which part comprises said origin of replication of said second micro-organism but not said nucleic acid of interest, by a part of said second vehicle, said part comprising said origin of replication of said first microorganism.
4. A method according to claim 3, wherein said part of said first vehicle has
25 different, non-palindromic overhangs that are not compatible with each other and that are compatible with the overhangs of said part of said second vehicle.
5. A method according to claim 3 or 4, wherein said parts are obtained by cleavage of said vehicles by *Sfi*I.
6. A method according to any one of claims 3-5, wherein said part of the first
30 vehicle comprising an origin of replication of said second micro-organism comprises a selection marker, such as for instance an antibiotic resistance gene, and wherein said part of the second vehicle comprising an origin of replication of said first micro-organism comprises a selection marker, such as for instance an antibiotic resistance gene.

7. A method according to any one of claims 1-6, wherein said nucleic acid of interest is inserted into said first vehicle and cloned in a culture of said second kind of micro-organism using a method selected from the group consisting of a ligation independent cloning (LIC) procedure, Gateway,
5 Univector Plasmid-fusion System (UPS) and LIC variants such as Enzyme-Free Cloning (EFC) and Sequence and Ligation Independent Cloning (SLIC).
8. A method according to any one of claims 3-7, wherein the process of inserting said nucleic acid of interest into said first vehicle and cloning it in a culture of said second kind of micro-organism is more efficient as compared to a process
10 of inserting said nucleic acid of interest into said second vehicle and cloning it in a culture of said first kind of micro-organism.
9. A method according to any one of claims 1-8, wherein said second micro-organism is *Escherichia coli*.
10. A method according to any one of claims 1-9, wherein said first micro-
15 organism is a micro-organism other than *Escherichia coli*, preferably a recalcitrant micro-organism.
11. A method according to any one of claims 1-10, further comprising allowing expression of said nucleic acid of interest by a culture of said first kind of micro-organism.
- 20 12. A method according to any one of claims 1-11, further comprising obtaining an expression product of said nucleic acid sequence of interest.
13. A method according to any one of claims 1-12, wherein said nucleic acid of interest encodes a multidomain protein and/or a membrane protein.
14. An expression product obtained by a method according to any one of claims
25 1-13.
15. A cloning assay wherein a nucleic acid of interest is cloned and expressed by a method according to any one of claims 1-13.
16. A kit of parts comprising:
 - a first nucleic acid vehicle which comprises an origin of replication of a
30 second kind of micro-organism; and
 - a second nucleic acid vehicle which comprises an origin of replication of a first kind of micro-organism;wherein each vehicle comprises at least two recombinase sites and/or restriction enzyme cleavage sites and wherein said recombinase sites and/or

restriction enzyme cleavage sites are preferably not present within said origins of replication.

17. A kit of parts according to claim 16, wherein each vehicle comprises at least two restriction enzyme cleavage sites which, upon cleaving, yield two different, non-palindromic overhangs that are not compatible with each other.
18. A kit of parts according to claim 16 or 17, wherein said first vehicle and said second vehicle comprise the same kind of restriction enzyme cleavage sites which, upon cleaving, yield two different, non-palindromic overhangs that are not compatible with each other.
19. A kit of parts according to any one of claims 16-18, wherein said restriction enzyme cleavage sites are *Sfi*I cleavage sites.
20. A kit of parts according to any one of claims 16-19, wherein said first vehicle comprises at least part of an *Escherichia coli* origin of replication.
21. A kit of parts according to any one of claims 16-20, wherein said second vehicle comprises at least part of an origin of replication of a micro-organism other than *Escherichia coli*, preferably an origin of replication of a recalcitrant micro-organism.
22. A kit of parts according to any one of claims 16-21, wherein said first vehicle comprises a selection marker, such as for instance an antibiotic resistance gene, and wherein said second vehicle comprises a selection marker, such as for instance an antibiotic resistance gene.
23. A *Lactococcus lactis* culture obtainable by a method according to any one of claims 1-13, wherein the amount of colony forming units per microgram nucleic acid of interest which was used in said method is at least 10^5 CFU/ μ g DNA.
24. A recombinant micro-organism comprising a nucleic acid vector, which vector comprises:
- an origin of replication of said kind of micro-organism;
 - a nucleic acid sequence of interest; and
 - at least two restriction enzyme cleavage sites which, upon cleaving, yield two different, non-palindromic overhangs that are not compatible with each other and wherein said restriction enzyme cleavage sites are not present within said origins of replication.
25. A micro-organism according to claim 24, which is a micro-organism other than *Escherichia coli*, preferably a recalcitrant micro-organism.

26. A micro-organism according to claim 24 or 25, wherein said restriction enzyme cleavage sites are *Sfi*I cleavage sites.

Figure 1




a Vector Backbone Exchange (VBEx)Introduce *SfiI* sites into plasmid vector of expression host**b** Ligation-Independent Cloning (LIC)

Figure 2A




Figure2B





Figure 3



INTERNATIONAL SEARCH REPORT

International application No

PCT/NL2008/050329

A. CLASSIFICATION OF SUBJECT MATTER

INV. C12N15/64 C12N15/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/40724 A (LIFE TECHNOLOGIES INC [US]; HARTLEY JAMES L [US]; BRASCH MICHAEL A [US] 19 December 1996 (1996-12-19) page 30, lines 26-27 page 5, lines 1-3; figure 1	1-3, 6, 8, 9, 11-16, 19-22, 24
X	WO 00/29000 A (LIFE TECHNOLOGIES INC [US]) 25 May 2000 (2000-05-25) page 48, line 9 page 44, lines 7-14; claim 14; figure 1	1-3, 6, 8, 9, 11-16, 19-22, 24
X	WO 91/02077 A (US HEALTH [US]) 21 February 1991 (1991-02-21) claim 3 ----- -/--	24-26

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

15 September 2008

Date of mailing of the international search report

22/09/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stolz, Beat

INTERNATIONAL SEARCH REPORT

International application No

PCT/NL2008/050329

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>XIANG HUA ET AL: "Expression and activity analysis of the human glutathione-S-transferase in Lactococcus lactis"</p> <p>WEISHENGWU XUEBAO - ACTA MICROBIOLOGICA SINICA, KEXUE CHUBANSHE, BEIJING, CN, vol. 40, no. 2, April 2000 (2000-04), pages 132-138, XP009091320 ISSN: 0001-6209 abstract</p>	1-3
A	<p>ASLANIDIS C ET AL: "LIGATION-INDEPENDENT CLONING OF PCR PRODUCTS (LIC-PCR)"</p> <p>NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 18, no. 20, 25 October 1990 (1990-10-25), pages 6069-6074, XP000159869 ISSN: 0305-1048 cited in the application</p>	1-5
L	<p>GEERTSMA ERIC R ET AL: "High-throughput cloning and expression in recalcitrant bacteria."</p> <p>NATURE METHODS SEP 2007, vol. 4, no. 9, September 2007 (2007-09), pages 705-707, XP002456639 ISSN: 1548-7091</p>	1-26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/NL2008/050329

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640724	A	19-12-1996	AT 222289 T 15-08-2002
			AU 724922 B2 05-10-2000
			AU 6384196 A 30-12-1996
			CA 2226463 A1 19-12-1996
			DE 69623057 D1 19-09-2002
			DE 69623057 T2 27-03-2003
			DK 937098 T3 02-12-2002
			EP 0937098 A1 25-08-1999
			ES 2181900 T3 01-03-2003
			HK 1019068 A1 17-04-2003
			JP 4020429 B2 12-12-2007
			JP 11507236 T 29-06-1999
			JP 2003299487 A 21-10-2003
			JP 2006087445 A 06-04-2006
			JP 2007020583 A 01-02-2007
			JP 2007306931 A 29-11-2007
			NZ 312332 A 28-01-2000
			NZ 500843 A 28-03-2002
			PT 937098 T 31-12-2002
			US 5888732 A 30-03-1999
WO 0029000	A	25-05-2000	AU 1721600 A 05-06-2000
			EP 1131078 A1 12-09-2001
WO 9102077	A	21-02-1991	AU 649228 B2 19-05-1994
			AU 6187990 A 11-03-1991
			AU 671228 B2 15-08-1996
			AU 6894894 A 17-11-1994
			CA 2064092 A1 29-01-1991
			EP 0484440 A1 13-05-1992
			JP 7255491 A 09-10-1995
			JP 4503309 T 18-06-1992
			US 5595895 A 21-01-1997